The bioinformatics startup has also invested in six other companies, committing $400 million to its data-sharing collaboration.
The company has identified markers of latent disease that it is now investigating to see if they could be useful for predicting progression to active infection.
The developer has presented clinical results that provide a base for completing development of a multi-protein test kit and conducting a clinical trial in advance of FDA submission.
The European Commission recently awarded the researchers €1.5 million to probe the mechanics of heart failure using proteomic, genomic, and epidemiological approaches.
The company this week published a study in JAMA describing the panel, which is intended for assessing the risk of adverse events in coronary heart disease patients.
The firm said it will use the funds to support development of new life science tools and clinical diagnostics based on its Somamer affinity agent technology.
While SomaScan is the company's main source of revenue, it continues to develop its Dx business and will launch its first test in the second half of 2016.
Under the agreement, BMS has access to the 1,310 reagents in the public version of SomaLogic's SOMAscan assay along with a number of custom-developed reagents.
Investigators from SomaLogic and elsewhere found proteins whose expression levels vary in Duchenne muscular dystrophy, often in conjunction with patients' age.
In Science this week: intellectual property landscape of CRISPR genome editing, and more.
A researcher has been convicted of conspiring to steal genetically engineered rice, Reuters reports.
Harvard Medical School's George Church says a woolly mammoth-elephant hybrid is only a few years away, according to the New Scientist.
Intel is ending its sponsorship of the International Science and Engineering Fair, the New York Times reports.